RxDoctor Payments Data

Anita Pillai Allen, MD

Urogynecology and Reconstructive Pelvic Surgery · Silver Spring, MDNPI 1174695647

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $31,000 of the $38,024 with a category attached, or 81.5%. Caldera Medical, Inc accounts for 84.9% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $22,461 and has fallen 99.4% since, to $125 in 2024.

$38,024in general payments, 2019–2025

Across 174 payments — averaging $218.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Caldera Medical, Inc$32K
  • Axonics, Inc.$4K
  • Pfizer$713
  • Astellas Pharma US Inc$404
  • AbbVie$269
  • Coloplast$182
  • plus $538 from 15 others

What the payments were for

  • Consulting fees$31,00082%
  • Travel & lodging$1,1673%
  • Food & beverage$5,53215%
  • Education$2311%
  • Gifts$930%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$53,215
Medicare patients
181
Services billed
604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron44$41,105
GemtesaVibegron39$36,163
Estradiol177$11,581
PremarinEstrogens, Conjugated23$9,529
Methenamine Hippurate27$4,062
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$404$41,10544 claims
Sumitomo Pharma America, Inc.Gemtesa$104$36,16339 claims
PfizerPremarin$713$9,52923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Marylandon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →